Donanemab (Synonyms: LY3002813) |
Catalog No.GC68996
One-Click Copy Product Info
|
Donanemab is a humanized IgG1 monoclonal antibody. Donanemab targets deposited Aβ42, and clear amyloid plaques in the brain through microglia-mediated phagocytosis. Donanemab mainly localized in the plasma and extracellular space and penetrates the brain across the blood–brain barrier to bind Aβ deposits. Donanemab is an effective treatment for Alzheimer's disease.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1931944-80-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Donanemab is a humanized IgG1 monoclonal antibody. Donanemab targets deposited Aβ42, and clear amyloid plaques in the brain through microglia-mediated phagocytosis. Donanemab mainly localized in the plasma and extracellular space and penetrates the brain across the blood–brain barrier to bind Aβ deposits. Donanemab is an effective treatment for Alzheimer's disease [1-5].
In the platelet-derived growth factor promoter-amyloid precursor protein (PDAPP) mouse model, Aβ42 levels in the hippocampus and cortex of mice were significantly reduced after Donanemab (1.5, 4, and 12.5mg/kg; sc; 6 months) treatment [6].
References:
[1]. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. Jama. 2023 Aug 8; 330(6): 512-527.
[2]. Mintun M, Ritchie CW, Solomon P, et al. Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial. Alzheimer's & Dementia. 2023 Dec; 19: e082733.
[3]. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. New England Journal of Medicine. 2021 May 6; 384(18): 1691-1704.
[4]. Jayaprakash N, Elumalai K. Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application. Chronic Diseases and Translational Medicine. 2024.
[5]. Kang C. Donanemab: first approval. Drugs. 2024 Oct; 84(10): 1313-1318.
[6]. DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron. 2012 Dec 6; 76(5): 908-920.
| Animal experiment [1]: | |
Animal models | Platelet-derived growth factor promoter-amyloid precursor protein (PDAPP) mouse model |
Preparation Method | PDAPP mice were injected subcutaneously weekly for 6 months with 1.5, 4, and 12.5mg/kg of Donanemab. |
Dosage form | 1.5, 4, and 12.5mg/kg; sc; 6 months |
Applications | PDAPP mice treated with the Donanemab antibody showed a significant dose-dependent decrease in Aβ42 levels in both the hippocampus and cortex. |
References: | |
| Cas No. | 1931944-80-7 | SDF | |
| Synonyms | LY3002813 | ||
| Formula | M.Wt | ||
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)